LEXSTON LIFE SCIENCES CORP. GRANTS STOCK OPTIONS
Vancouver, British Columbia, July 5, 2021. Lexston Life Sciences Corp. (CSE: LEXT) (“Lexston”) granted 2,500,000 stock options to its directors, officers, consultants and employees. Each stock option is exercisable at $0.175 per share. The options vest immediately and expire on July 5, 2026. All options were granted pursuant to the 10% rolling stock option plan of Lexston dated January 15, 2021 (the “Plan”). As of the date of this news release Lexston has 4,500,000 stock options granted and 496,826 stock options available for future grants.
About Lexston Life Sciences Corp.
Lexston Life Sciences Corp. (“Lexston”) is a Canadian biotechnology company providing cannabis testing and research services. Lexston is also in the process of securing licensing under the exemptions prescribed by section 56 of the Controlled Drugs and Substances Act (Canada) to enable the expansion of prescribed by section 56 of the Controlled Drugs and Substances Act (Canada) to enable the expansion of psychedelic molecules in the lab and point of care. Lexston intends to develop and validate methods for standardized manufacturing of plant derived psychedelics in support of burgeoning trials in the ﬁeld of mental health and wellness.
On Behalf of the Board of Directors
LEXSTON LIFE SCIENCES CORP.
Chief Executive Oﬃcer
Telephone: (604) 928-8913
Neither the Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.
929 Mainland Street Vancouver, BC V6B 1S3